- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.08. | Gilead's HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability | ||
| 05.08. | 'No discussions' ongoing for AstraZeneca-Bristol Myers merger: Reuters | ||
| 04.08. | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling | ||
| 04.08. | As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill | ||
| 04.08. | Drugmakers don't have 'duty to innovate', California court rules, backing Gilead in HIV drug litigation | ||
| 04.08. | Pfizer unveils additional $2.5B in planned cost savings through 2029 | ||
| 04.08. | J&J innovative medicine chief Jennifer Taubert to retire, handing reins to North America head | ||
| 04.08. | 'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2 | ||
| 04.08. | Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer | ||
| 03.08. | In a first, Otsuka's Voyxact stabilizes IgAN patients' kidney function decline to normal levels | ||
| 03.08. | Curium strikes up to $8B deal for radiopharma rival Lantheus | ||
| 03.08. | Supernus, Indivior merge to create CNS-focused company and expand BD opportunities | ||
| 03.08. | Amgen says patient health data, IP stolen in cybersecurity breach | ||
| 03.08. | Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims | ||
| 03.08. | Gerresheimer sheds pair of pharma packaging units in deal valued at €1.5B | ||
| 03.08. | After 6-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company | ||
| 03.08. | Editor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea | ||
| 01.08. | Regulatory tracker: Ahead of FDA verdicts, EU clears AbbVie's Rinvoq in alopecia, vitiligo | ||
| 31.07. | Amylyx demystifies post-bariatric hypoglycemia with patient education website | ||
| 31.07. | Daiichi Sankyo flags accounting error, as shares tank despite revenue beat | ||
| 31.07. | AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market | ||
| 31.07. | Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis | ||
| 30.07. | Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie | ||
| 30.07. | YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort | ||
| 30.07. | Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.